Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propafenone in the Treatment of Atrial Fibrillation
NCT03674658Completed
- Sponsor
- TSH Biopharm Corporation Limited
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of propafenone in Atrial fibrillation (AFib) (2 arms), sponsored by TSH Biopharm Corporation Limited. Primary endpoint: Proportion of patients with recurrent AF at 24 weeks. Started Jul 2019; status: completed.
02
Drugs
propafenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03674658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674658.